FDA Public Health Advisory

Wellbutrin (bupropion) is a member of a class of drugs called "Dopamine transport blockers." It is most often prescribed for the treatment of depression. In 2004, the manufacturer of Wellbutrin, GlaxoSmithKline, along with the FDA, issued a warning to healthcare professionals stating in part, that patients being treated with antidepressants may "experience worsening of their depression and/or the emergence of suicidal ideation and behavior". Professionals were encouraged to watch closely for signs of "clinical worsening and suicidality" in their patients, particularly when starting or stopping the drug, as well as when dosages are changed.

In October 2004 the FDA approved the following for inclusion on a "black box" warning for the Wellbutrin label:

"Antidepressants increase the risk of suicidal thinking and behavior (suicidality) in children and adolescents with MDD and other psychiatric disorders."

Register your Wellbutrin Case

If you or a loved one has been the victim of violent, destructive, or irrational behavior induced by the use of Wellbutrin, you may qualify for damages or remedies that may be awarded in a possible Wellbutrin class action lawsuit.